NCT06709859 2025-07-17
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Shandong Public Health Clinical Center
Phase 2 Recruiting
Clinical Trials
4 trialsNCT06071013 2025-01-23
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
China Medical University Hospital
Phase 1/2 Recruiting
NCT06486142 2024-07-03
ERIS
Region Skane
Phase 3 Recruiting
NCT04909073 2024-05-17
Observational Study of Afatinib 30 mg Daily
National University Hospital, Singapore
Recruiting